
Sanjay Sethi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7568613/publications.pdf Version: 2024-02-01



SANIAV SETHI

#	Article	IF	CITATIONS
1	Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 2355-2365.	13.9	1,046
2	New Strains of Bacteria and Exacerbations of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2002, 347, 465-471.	13.9	931
3	Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. Clinical Microbiology Reviews, 2001, 14, 336-363.	5.7	493
4	Bacterial Infection in Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1992, 146, 1067-1083.	2.9	486
5	Airway Inflammation and Bronchial Bacterial Colonization in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 991-998.	2.5	331
6	Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease. Journal of Clinical Microbiology, 2014, 52, 2813-2823.	1.8	272
7	Targeting Nrf2 Signaling Improves Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in a Mouse Model. Science Translational Medicine, 2011, 3, 78ra32.	5.8	271
8	Persistent Colonization byHaemophilus influenzaein Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 266-272.	2.5	270
9	<i>Pseudomonas aeruginosa</i> in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 853-860.	2.5	253
10	Moraxella catarrhalisin Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 195-199.	2.5	247
11	Infectious Etiology of Acute Exacerbations of Chronic Bronchitis. Chest, 2000, 117, 380S-385S.	0.4	243
12	COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 235-256.	0.7	240
13	Haemophilus haemolyticus:A Human Respiratory Tract Commensal to Be Distinguished fromHaemophilus influenzae. Journal of Infectious Diseases, 2007, 195, 81-89.	1.9	205
14	Impaired Phagocytosis of NontypeableHaemophilus influenzaeby Human Alveolar Macrophages in Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2006, 194, 1375-1384.	1.9	197
15	Airway Inflammation and Etiology of Acute Exacerbations of Chronic Bronchitis. Chest, 2000, 118, 1557-1565.	0.4	196
16	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
17	Significance of the microbiome in obstructive lung disease. Thorax, 2012, 67, 456-463.	2.7	190
18	Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 356-361.	2.5	174

#	Article	IF	CITATIONS
19	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	2.5	166
20	Standardizing Measurement of Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 323-329.	2.5	160
21	Inflammatory Profile of New Bacterial Strain Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 491-497.	2.5	156
22	Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory Research, 2010, 11, 10.	1.4	155
23	Bacterial Infection and the Pathogenesis of COPD. Chest, 2000, 117, 286S-291S.	0.4	146
24	Strain-specific Immune Response toHaemophilus influenzaein Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 448-453.	2.5	139
25	Haemophilus influenzaefrom Patients with Chronic Obstructive Pulmonary Disease Exacerbation Induce More Inflammation than Colonizers. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 85-91.	2.5	139
26	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	3.1	138
27	Exacerbations of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2007, 4, 554-564.	3.5	135
28	<scp>COPD</scp> and the microbiome. Respirology, 2016, 21, 590-599.	1.3	130
29	Novel Use of Home Pulse Oximetry Monitoring in COVIDâ€19 Patients Discharged From the Emergency Department Identifies Need for Hospitalization. Academic Emergency Medicine, 2020, 27, 681-692.	0.8	127
30	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	2.5	121
31	Bacteria in Exacerbations of Chronic Obstructive Pulmonary Disease: Phenomenon or Epiphenomenon?. Proceedings of the American Thoracic Society, 2004, 1, 109-114.	3.5	119
32	T-Regulatory Cells and Programmed Death 1 ⁺ T Cells Contribute to Effector T-Cell Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 40-50.	2.5	110
33	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β ₂ -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE ² SPOND). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 559-567.	2.5	109
34	The Role of Bacteria in Exacerbations of COPD. Chest, 2000, 118, 204-209.	0.4	106
35	Phagocytic Dysfunction of Human Alveolar Macrophages and Severity of Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2013, 208, 2036-2045.	1.9	106
36	Bacteria Challenge in Smoke-exposed Mice Exacerbates Inflammation and Skews the Inflammatory Profile. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 666-675.	2.5	104

#	Article	IF	CITATIONS
37	Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value in Health, 2010, 13, 965-975.	0.1	97
38	Oralâ€lung microbiome interactions in lung diseases. Periodontology 2000, 2020, 83, 234-241.	6.3	97
39	IL-17A and the Promotion of Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 428-437.	2.5	95
40	Bacterial Colonization Increases Daily Symptoms in Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2014, 11, 303-309.	1.5	93
41	Impaired Alveolar Macrophage Response toHaemophilusAntigens in Chronic Obstructive Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 31-40.	2.5	92
42	Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE, 2016, 11, e0163716.	1.1	92
43	Simultaneous Respiratory Tract Colonization by Multiple Strains of NontypeableHaemophilus influenzaein Chronic Obstructive Pulmonary Disease: Implications for Antibiotic Therapy. Journal of Infectious Diseases, 1999, 180, 404-409.	1.9	91
44	Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respiratory Research, 2014, 15, 124.	1.4	91
45	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.4	91
46	Inflammation in COPD: Implications for Management. American Journal of Medicine, 2012, 125, 1162-1170.	0.6	86
47	Early Hospital Readmissions after an Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the Nationwide Readmissions Database. Annals of the American Thoracic Society, 2018, 15, 837-845.	1.5	84
48	Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax, 2014, 69, 811-818.	2.7	83
49	Molecular Basis of Increased Serum Resistance among Pulmonary Isolates of Non-typeable Haemophilus influenzae. PLoS Pathogens, 2011, 7, e1001247.	2.1	82
50	Infectious exacerbations of chronic bronchitis: diagnosis and management. Journal of Antimicrobial Chemotherapy, 1999, 43, 97-105.	1.3	77
51	Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer. International Journal of COPD, 2011, 6, 113.	0.9	74
52	Lymphocyte Proliferative Response to P6 ofHaemophilus influenzaels Associated with Relative Protection from Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 967-971.	2.5	72
53	Characterizing and Quantifying the Symptomatic Features of COPD Exacerbations. Chest, 2011, 139, 1388-1394.	0.4	71
54	A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 153	1.4	71

#	Article	IF	CITATIONS
55	Antibiotics for treatment and prevention ofÂexacerbations of chronic obstructive pulmonary disease. Journal of Infection, 2013, 67, 497-515.	1.7	69
56	Moxifloxacinversusamoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. European Respiratory Journal, 2012, 40, 17-27.	3.1	68
57	Outer Membrane Protein P6 of Nontypeable Haemophilus influenzae Is a Potent and Selective Inducer of Human Macrophage Proinflammatory Cytokines. Infection and Immunity, 2005, 73, 2728-2735.	1.0	67
58	<i>Pseudomonas aeruginosa</i> Population Biology in Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2009, 200, 1928-1935.	1.9	67
59	Human Immune Response to NontypeableHaemophilus influenzaein Chronic Bronchitis. Journal of Infectious Diseases, 1997, 176, 1247-1252.	1.9	63
60	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278.	2.5	60
61	Large-Scale, Ion-Current-Based Proteomics Investigation of Bronchoalveolar Lavage Fluid in Chronic Obstructive Pulmonary Disease Patients. Journal of Proteome Research, 2014, 13, 627-639.	1.8	59
62	New Paradigms in the Pathogenesis of Chronic Obstructive Pulmonary Disease II. Proceedings of the American Thoracic Society, 2009, 6, 532-534.	3.5	58
63	Role of nontypeable Haemophilus Influenzae in exacerbations and progression of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2006, 12, 118-124.	1.2	57
64	<i>Haemophilus influenzae</i> genome evolution during persistence in the human airways in chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3256-E3265.	3.3	57
65	Chronic Obstructive Pulmonary Disease. Drugs and Aging, 2002, 19, 761-775.	1.3	55
66	Pathogenesis of Bacterial Exacerbations of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2006, 3, 109-115.	0.7	55
67	Systemic and Mucosal Antibody Response toMoraxella catarrhalisafter Exacerbations of Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2002, 185, 632-640.	1.9	54
68	New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases, 2004, 17, 113-119.	1.3	54
69	Effects of Bacterial Infection on Airway Antimicrobial Peptides and Proteins in COPD. Chest, 2011, 140, 611-617.	0.4	54
70	Future Research Directions in Pneumonia. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 256-263.	2.5	54
71	Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine, 2009, 28, 279-289.	1.7	52
72	Expression of a peroxiredoxin–glutaredoxin byHaemophilus influenzaein biofilms and during human respiratory tract infection. FEMS Immunology and Medical Microbiology, 2005, 44, 81-89.	2.7	51

#	Article	IF	CITATIONS
73	The lung microbiome and exacerbations of COPD. Current Opinion in Pulmonary Medicine, 2016, 22, 196-202.	1.2	50
74	Moraxella catarrhalisacquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infectious Diseases, 2009, 9, 178.	1.3	48
75	Antigenic Specificity of the Mucosal Antibody Response to Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2005, 73, 8161-8166.	1.0	47
76	Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clinical Therapeutics, 2001, 23, 1683-1706.	1.1	46
77	Identification of Surface Antigens of Moraxella catarrhalis as Targets of Human Serum Antibody Responses in Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2005, 73, 3471-3478.	1.0	43
78	Differential Genome Contents of Nontypeable Haemophilus influenzae Strains from Adults with Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2006, 74, 3366-3374.	1.0	43
79	Outer membrane protein CD of Branhamella catarrhalis: Sequence conservation in strains recovered from the human respiratory tract. Microbial Pathogenesis, 1995, 19, 215-225.	1.3	42
80	Molecular Diagnosis of Respiratory Tract Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2011, 52, S290-S295.	2.9	42
81	Performance of the EXAcerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in Three Clinical Trials of Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2014, 11, 316-325.	1.5	41
82	Role of Infections. Clinics in Chest Medicine, 2014, 35, 87-100.	0.8	40
83	Optimizing antibiotic selection in treating COPD exacerbations. International Journal of COPD, 2008, Volume 3, 31-44.	0.9	38
84	Analysis of Antigenic Structure and Human Immune Response to Outer Membrane Protein CD of <i>Moraxella catarrhalis</i> . Infection and Immunity, 1999, 67, 4578-4585.	1.0	36
85	Human Immune Response to Outer Membrane Protein CD of Moraxella catarrhalis in Adults with Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2003, 71, 1288-1294.	1.0	34
86	Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort. Open Forum Infectious Diseases, 2020, 7, ofz546.	0.4	33
87	Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic Bronchitis. Antimicrobial Agents and Chemotherapy, 2005, 49, 153-160.	1.4	32
88	A Clonal Group of Nontypeable Haemophilus influenzae with Two IgA Proteases Is Adapted to Infection in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2011, 6, e25923.	1.1	30
89	Sequence Stability of the Gene Encoding Outer Membrane Protein P2 of NontypeableHaemophilus influenzaein the Human Respiratory Tract. Journal of Infectious Diseases, 2002, 185, 627-631.	1.9	29
90	<i>Pseudomonas</i> infection in chronic obstructive pulmonary disease. Future Microbiology, 2012, 7, 1129-1132.	1.0	29

#	Article	IF	CITATIONS
91	Expression of IgA Proteases by <i>Haemophilus influenzae</i> in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2015, 212, 1798-1805.	1.9	29
92	Serum Antipneumococcal Antibodies and Pneumococcal Colonization in Adults with Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2007, 196, 928-935.	1.9	28
93	Antibiotic Resistance in Sputum Isolates of <i>Streptococcus pneumoniae</i> in Chronic Obstructive Pulmonary Disease is Related to Antibiotic Exposure. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 337-344.	0.7	28
94	IL-18 associated with lung lymphoid aggregates drives IFNÎ ³ production in severe COPD. Respiratory Research, 2017, 18, 159.	1.4	28
95	Horizontal Transfer of the Gene Encoding Outer Membrane Protein P2 of NontypeableHaemophilus influenzae,in a Patient with Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2003, 188, 114-117.	1.9	27
96	Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology—impact on approaches to risk stratification and therapy. Infectious Disease Clinics of North America, 2004, 18, 861-882.	1.9	26
97	Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 4151-4158.	1.4	26
98	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine, 2019, 153, 38-43.	1.3	25
99	Acute Exacerbations of Chronic Bronchitis. Drugs and Aging, 2001, 18, 1-11.	1.3	24
100	AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. International Journal of COPD, 2019, Volume 14, 667-682.	0.9	24
101	C-Reactive Protein at Discharge, Diabetes Mellitus and ≥1 Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 311-320.	0.7	23
102	Pathogenesis and Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 192-203.	0.8	22
103	Serial Isolates of Persistent <i>Haemophilus influenzae</i> in Patients with Chronic Obstructive Pulmonary Disease Express Diminishing Quantities of the HMW1 and HMW2 Adhesins. Infection and Immunity, 2008, 76, 4463-4468.	1.0	22
104	A Sputum Proteomic Signature That Associates with Increased IL- $1\hat{l}^2$ Levels and Bacterial Exacerbations of COPD. Lung, 2016, 194, 363-369.	1.4	22
105	Lower Airway Bacterial Colonization Patterns and Species-Specific Interactions in Chronic Obstructive Pulmonary Disease. Journal of Clinical Microbiology, 2018, 56, .	1.8	22
106	Identification of Domains of the Hag/MID Surface Protein Recognized by Systemic and Mucosal Antibodies in Adults with Chronic Obstructive Pulmonary Disease following Clearance of <i>Moraxella catarrhalis</i> . Vaccine Journal, 2009, 16, 653-659.	3.2	19
107	Etiology and Management of Infections in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 1999, 6, 327-332.	0.3	18
108	RSV Infection — Not for Kids Only. New England Journal of Medicine, 2005, 352, 1810-1812.	13.9	18

#	Article	IF	CITATIONS
109	Human Antibody Response to Outer Membrane Protein G1a, a Lipoprotein of Moraxella catarrhalis. Infection and Immunity, 2005, 73, 6601-6607.	1.0	18
110	Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms. PLoS ONE, 2015, 10, e0134209.	1.1	18
111	Coinfection in Exacerbations of COPD. Chest, 2006, 129, 223-224.	0.4	17
112	Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones?. Current Opinion in Infectious Diseases, 2019, 32, 143-151.	1.3	17
113	Human serum and mucosal antibody responses to outer membrane protein G1b ofMoraxella catarrhalisin chronic obstructive pulmonary disease. FEMS Immunology and Medical Microbiology, 2006, 46, 139-146.	2.7	16
114	Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspensionâ,,¢ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respiratory Research, 2016, 17, 109.	1.4	16
115	Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. Respiratory Research, 2019, 20, 190.	1.4	16
116	Calcium Restores the Macrophage Response to Nontypeable <i>Haemophilus influenzae</i> in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 728-737.	1.4	15
117	Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. Annals of Clinical Microbiology and Antimicrobials, 2005, 4, 5.	1.7	14
118	Moxifloxacin for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2005, 41, S177-S185.	2.9	14
119	Design and validation of a supragenome array for determination of the genomic content of Haemophilus influenzae isolates. BMC Genomics, 2013, 14, 484.	1.2	14
120	Long-term macrolide therapy in chronic obstructive pulmonary disease. Cmaj, 2014, 186, 1148-1152.	0.9	14
121	<p>Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies</p> . International Journal of COPD, 2020, Volume 15, 2889-2900.	0.9	14
122	Use of Moraxella catarrhalis Lipooligosaccharide Mutants To Identify Specific Oligosaccharide Epitopes Recognized by Human Serum Antibodies. Infection and Immunity, 2009, 77, 4548-4558.	1.0	13
123	Chronic Obstructive Pulmonary Disease and Infection. Disruption of the Microbiome?. Annals of the American Thoracic Society, 2014, 11, S43-S47.	1.5	13
124	Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics, 2002, 57, 56-61.	0.3	13
125	Modulation of Airway Inflammation by Haemophilus influenzae Isolates Associated with Chronic Obstructive Pulmonary Disease Exacerbation. Proceedings of the American Thoracic Society, 2006, 3, 482-483.	3.5	11
126	A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. International Journal of COPD, 2011, 6, 373.	0.9	11

#	Article	IF	CITATIONS
127	Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology and Therapeutics, 2019, 57, 101808.	1.1	11
128	INFLAMMATORY MARKERS IN BACTERIAL EXACERBATIONS OF COPD. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 132-132.	2.5	10
129	The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Current Infectious Disease Reports, 2003, 5, 9-15.	1.3	10
130	Bronchodilator Combination Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Current Clinical Pharmacology, 2011, 6, 48-61.	0.2	10
131	Validation of fitness tracker for sleep measures in women with asthma. Journal of Asthma, 2019, 56, 719-730.	0.9	10
132	Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate. PLoS ONE, 2019, 14, e0207675.	1.1	10
133	Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population. International Journal of COPD, 2022, Volume 17, 593-608.	0.9	10
134	Pseudomonas aeruginosa Colonization and COPD: The Chicken or the Egg?. Archivos De Bronconeumologia, 2022, 58, 539-541.	0.4	10
135	MANAGEMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS. Infectious Diseases in Clinical Practice, 1998, 7, S300-S308.	0.1	9
136	Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem. Current Medical Research and Opinion, 2004, 20, 1511-1521.	0.9	9
137	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β ₂ -agonist fixed-dose combination: RE ² SPOND rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	0.9	9
138	The reliability and validity of patient-reported chronic obstructive pulmonary disease exacerbations. Current Opinion in Pulmonary Medicine, 2014, 20, 146-152.	1.2	8
139	Infections in "Noninfectious―Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S221-S226.	1.5	8
140	Systemic Inflammation in Predicting COPD Exacerbations. JAMA - Journal of the American Medical Association, 2013, 309, 2390.	3.8	7
141	Treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 439-451.	0.8	7
142	Personalised medicine in exacerbations of COPD: the beginnings. European Respiratory Journal, 2012, 40, 1318-1319.	3.1	6
143	Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD. International Journal of COPD, 2015, 10, 985.	0.9	6
144	<p>Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD</p> . International Journal of COPD, 2019, Volume 14, 2947-2958.	0.9	6

#	Article	IF	CITATIONS
145	The problems of meta-analysis for antibiotic treatment of chronic obstructive pulmonary disease, a heterogeneous disease: a commentary on Puhan et al. BMC Medicine, 2008, 6, 29.	2.3	5
146	Antibiotics in acute exacerbations of chronic bronchitis. Expert Review of Anti-Infective Therapy, 2010, 8, 405-417.	2.0	5
147	Human Models of Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 691-692.	2.5	5
148	The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD. Immunological Investigations, 2016, 45, 130-147.	1.0	5
149	To Improve COPD Care. Chest, 2018, 154, 235-237.	0.4	5
150	Chronic Obstructive Pulmonary Disease in the Intensive Care Unit: Antibiotic Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 830-841.	0.8	5
151	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspensionâ,,¢ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 21-33.	0.5	5
152	Proteomic Network Analysis of Bronchoalveolar Lavage Fluid in Ex-Smokers to Discover Implicated Protein Targets and Novel Drug Treatments for Chronic Obstructive Pulmonary Disease. Pharmaceuticals, 2022, 15, 566.	1.7	5
153	The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2011, 5, 207-216.	1.0	4
154	Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
155	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respiratory Research, 2020, 21, 128.	1.4	4
156	Prediction model development of women's daily asthma control using fitness tracker sleep disruption. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 548-555.	0.8	4
157	Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662090527.	1.0	3
158	Impact of Acute Exacerbations on the Natural History of Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 2005, 12, S16-S18.	0.3	2
159	A 5-day course of systemic corticosteroids is adequate to treat acute exacerbations of chronic obstructive pulmonary disease. Evidence-Based Medicine, 2014, 19, 57-57.	0.6	2
160	Increased Fisher's information for parameters of association in count regression via extreme ranks. Communications in Statistics - Theory and Methods, 2018, 47, 1181-1203.	0.6	2
161	Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. International Journal of COPD, 2018, Volume 14, 117-127.	0.9	2
162	Enhanced Drug and Device Development by Targeting "Relief of Dyspnea― Chest, 2020, 158, 464-466.	0.4	2

#	Article	IF	CITATIONS
163	Gatifloxacin in community-acquired respiratory tract infection. Expert Opinion on Pharmacotherapy, 2003, 4, 1847-1855.	0.9	1
164	Bacterial Load and Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1049-1049.	2.5	1
165	Chance Favors the Prepared Mind. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1070-1071.	2.5	1
166	Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease. Data in Brief, 2019, 26, 104277.	0.5	1
167	Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2020, 13, 103-113.	1.3	1
168	Antibiotic Retreatment for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 481-482.	2.5	1
169	What is bacterial colonisation in COPD?. , 0, , 161-171.		1
170	Bacterial infection. , 0, , 97-113.		1
171	Hacking the Immune Response to Infection in Chronic Obstructive Pulmonary Disease. , 2020, , .		1
172	Inflammation and Acute Exacerbations of Chronic Bronchitis. Chest, 2001, 120, 1423.	0.4	0
173	Bacteria and COPD Exacerbations Redux. Chest, 2001, 119, 666-667.	0.4	0
174	Are ColonialHaemophilus influenzaeResponsible for Exacerbations of Chronic Obstructive Pulmonary Disease After All?. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 194-195.	2.5	0
175	Bronchoscopic Valor in Exacerbations of Chronic Bronchitis. Journal of Bronchology, 2007, 14, 137-139.	0.2	0
176	Surveillance Cultures in Respiratory Tract Infections. Chest, 2012, 141, 577-578.	0.4	0
177	Reply: Looking for Predictors of Early Readmission in Chronic Obstructive Pulmonary Disease: Every Effort Is Required. Annals of the American Thoracic Society, 2018, 15, 1367-1367.	1.5	0
178	Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?. European Respiratory Journal, 2019, 54, 1901405.	3.1	0
179	Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2020, 14, 239-247.	1.0	0
180	Response to the Letter to the Editor Regarding "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies―[Response to Letter]. International Journal of COPD, 2021, Volume 16, 1227-1229.	0.9	0

#	Article	IF	CITATIONS
181	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. , 2012, , 183-186.		Ο
182	Infectious Mechanisms Regulating Susceptibility to Acute Exacerbations of COPD. , 2013, , 159-176.		0
183	Association of Chronic Lower Respiratory Disease With County Health Disparities in New York State. JAMA Network Open, 2021, 4, e2134268.	2.8	0
184	Interpreting Recent Developments in COPD Treatments. Journal of Family Practice, 2018, 67, S33-S39.	0.2	0